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Abstract 
BACKGROUND: Untreated or undertreated, pulmonary tuberculosis could cause severe complications until 
death. After treatment, residual lesions might occur. The presence of residual lesions is varied, including fibrosis, 
cavity, bronchiectasis and calcification. Transforming growth factor-β (TGF-β) is a cytokine associated with lung 
inflammation, which plays a role in lung fibrosis. However, only a few studies have assessed the serum level of 
TGF-β in post-treatment tuberculosis patients.  
AIM: The main objective of this study was to determine the correlation between TGF-β levels and pulmonary 
fibrosis in patients with pulmonary tuberculosis. 
DESIGN: A group of 51 patients that had undergone anti-tuberculosis treatment were observed, consisting of 31 
men, 20 women. Of all patients, there were 26 people with a smoking history, including 25 men and 1 woman. All 
patients had been recovered, confirmed by the clinical state, laboratory and radiology examination. The ELISA 
test was performed to measure TGF-β level, while the chest X-ray was used to look for the occurrence of 
pulmonary fibrosis. 
RESULTS: The mean level of TGF-β in patients with a lesion (+) was 7628.02 (SD: ± 4928.38) while the mean 
level of TGF-β in patients with a lesion (-) was 2315.11 (SD: ± 505.83). The statistical test showed a significant 
relationship between TGF-β level and fibrosis lesion (p < 0.001). 
CONCLUSION: TGF-β level was significantly higher in post-tuberculosis patients with pulmonary fibrosis. 
 
 
 
 
Introduction 
 
Tuberculosis (TB) is an infectious disease 
caused by germs from the Mycobacterium 
tuberculosis. Pulmonary TB is a type of TB infections 
which invade the pulmonary parenchyma, including 
respiratory bronchiole and alveolus [1]. According to 
the Global Tuberculosis Report 2016, Indonesia is the 
second country with the highest incidence of 
pulmonary TB after India and followed by China [2]. 
TB patients who are recovering from TB 
usually have residual lesions and sign and symptoms 
similar to chronic obstructive pulmonary disease 
(COPD) such as shortness of breath during activity 
[3], [4]. In a case series study, it showed that in 
patients with post pulmonary TB, some of them 
develop a reduction of lung functions, with the majority 
of patients had a moderate obstruction and mild 
restriction [3]. TB sequelae is a condition of which 
there is permanent deformity after TB treatment. TB 
sequelae may appear in lung and extra lung. Lung 
fibrosis is one of the variations in residual lesions that 
occur in the lung parenchyma [5], [7]. 
To find out the process of fibrosis formation, 
recent studies had discussed the molecular level of 
lung fibrosis of which several inflammatory cytokines 
were found to be involved in defence mechanisms 
against bacterial infections, including pro-inflammatory 
cytokines such as interferon-γ (IFN-γ), and anti-
inflammatory cytokines such as Tumor Necrosis 
Factor Alpha (TNF-α), and Transforming Growth 
Factor – β (TGF – β) [4], [6], [7]. TGF – β is a cytokine 
that plays an important role in cell proliferation and 
differentiation. TGF-β has been recognised as the 
suppressor in the immune system and stimulator in 
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the pathogenesis of pulmonary fibrosis. Thus 
excessive production of TGF-β can cause the 
excessive deposit of scar tissue and fibrosis [7], [8], 
[9]. 
Smoking is one of the aggravating factors in 
forming lung fibrosis. Cigarette smoke can induce pro-
inflammatory and immunosuppressive cytokines that 
stimulate fibrogenesis in post-pulmonary TB. A study 
showed the increased level of TNF-α could decrease 
the lung functions in post-pulmonary TB [4].  
The studies of TGF-β level in post-TB patients 
have not been widely conducted in Indonesia. Figen 
Devici et al. found that inactive TB patients, inactive 
TB and healthy people, TGF-β level were 258.1 ± 
306.6, 185.1 ± 216.5, 110.3 ± 83.2 [10]. A Study about 
the correlation between TGF-β level and pulmonary 
fibrosis in post-TB patients has never been conducted 
in one of the provinces in Sumatera. These facts 
interest the authors to conduct a study about the 
relationship between TGF-β level and pulmonary 
fibrosis in post-TB-patients. 
 
 
Material and Methods 
 
Study population 
This study was an analytical study with cross-
sectional design and conducted in Haji Adam Malik 
General Hospital, Medan, North Sumatera.  
 
Inclusion Criteria 
1. Patients with pulmonary TB who had been 
recovered, confirmed by negative smear examination 
in the sixth month of treatment. 
2. Patients aged over 17 years. 
3. Willing to follow the study after receiving 
information about this study (written informed 
consent). 
 
Exclusion criteria 
1. Patients diagnosed with asthma; and/or 
2. Patients suffer from diseases that can 
interfere with lung function.  
 
Procedures 
After had been contacted via mobile phone, 
all participants were informed about the content of the 
study, and if they were willing to participate, they were 
asked to come to the hospital. Then, they needed to 
sign the informed consent and were interviewed about 
the history of TB. TGF-β examination was conducted 
from a vein blood sample, processed with Enzyme 
Link Immunosorbent Assay (ELISA) by using TGF-β 
kit. Pulmonary fibrosis was confirmed by Chest X-Ray.  
  
Statistical Analysis 
All data were analysed using SPSS version 
23. Then, they were analysed if they were normally 
distributed by Kolmogoroff-Smirnov. In this data, 
Independent T-test was used to determine the 
significant correlation between TGF-β levels and 
pulmonary fibrosis. P-value < 0.05 considered to be 
significant. 
 
 
Results 
 
This study involving 51 subjects who matched 
inclusion criteria and did not have any exclusion 
criteria. The study samples were post-TB patients and 
were grouped based on gender, age, smoking history, 
Brinkman-Index, level of education, occupational, and 
fibrosis lesson (Table 1).  
Table 1: Characteristics of study subjects based on gender, 
age, smoking history, Brinkman Index, level of education, 
occupational, and fibrosis lesson 
Variable  N (%) 
Gender   
Male  31 (60.80) 
Female 
Total 
 
 
20 (39.20) 
51 (100) 
Age   
15-30 Years  16 (31.4) 
31-45 Years  12 (23.5) 
46-60 Years  22 (43.1) 
61-75 Years 
Total 
Average Age (Year) 
 
 
40.75 ± 14.3 
1 (2.0) 
51 (100) 
 
Smoking History  
Yes 
 
 
 
26 (51.0) 
No 
Total 
 25 (49.0) 
51 (100) 
Brinkman Index   
Mild  10 (38.4) 
Moderate  10 (38.4) 
Severe 
Total 
 
 
6 (23.2) 
26 (100) 
Level of Education   
< Senior High School  24 (47.1) 
Senior High School  16 (31.4) 
Diploma  4 (7.8) 
Bachelor 
Total 
 
 
7 (13.7) 
51 (100) 
Occupational   
Indoor  29 (56.9) 
Outdoor 
Total 
 22 (43.1) 
51 (100) 
Fibrosis Lesion   
Yes   42 (82.4) 
No 
Total 
 9 (17.6) 
51 (100) 
 
From the table, we showed the majority of 
participants were men consisted of 31 people 
(60.80%), while the female 20 (39.20%). Based on 
age, the highest age group was the age group of 46-
60 years, which consisted of 22 people (43.1%), with 
an average age of 40.75 years. Study subjects who 
had a smoking history were 26 people (51.0%), with 
mild and moderate Brinkman Index in 10 people 
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(38.4%), respectively and severe Brinkman Index in 6 
people (23.2%) and subjects who had no smoking 
history were 25 people (49.0%). The characteristics of 
the study subjects based on the presence of fibrosis 
lesions, there were 42 subjects (82.4%) with fibrosis 
lesions on the chest X-ray and 9 subjects without 
fibrosis lesions in the chest X-ray (17.6%). 
Table 2: TGF-β level of study subject 
Variable Min - Max Mean SD Median 
TGF-β (pg/ml) 
 Smoking History (+) 
 Smoking History (-) 
692 – 19100 
692 – 16700 
1590 - 19100 
6690.45 
6621.50 
6762.16 
4913.46 
4856.77 
5070.95 
5190.00 
5370.00 
4780.00 
 
Table 2 shows that TGF-β level in the study 
subjects obtained an average level of 6690.45 pg/ml ± 
4913.46 pg/ml, median 5190 pg/ml, with a minimum 
value of 692 pg/ml and maximum value 19100 pg/ml. 
The study subjects with smoking history status 
obtained an average level of TGF-β were 6621.50 
pg/ml ± 4856.77 pg/ml SD, median 5370.00 pg/ml, 
and a minimum value of 692 pg/ml and a maximum of 
16700 pg/ml. In the study subjects without smoking 
history status, the average level of TGF-β was 
6762.16 pg/ml ± 5070.95 pg/ml SD, median 4780.00 
pg/ml, and a minimum value of 1590 pg/ml and a 
maximum of 19100 pg/ml. 
Table 3: Correlation between TGF-β level and pulmonary 
fibrosis 
Fibrosis 
Lesion 
TGF-β Level 
Mean SD Median Min-Maks p-value 
(+) 7628.02 4928.38 7185.00 692-19100 0.001
* 
(-) 2315.11 505.83 2177.00 1620- 3430  
*Significant with the independent t-test correlation test. 
 
The correlation between TGF-β level and the 
presence or absence of pulmonary fibrosis in a chest 
X-ray can be seen in Table 4. Based on the 
independent t-test, the p-value was 0.001. This result 
indicated that there was a significant correlation 
between TGF-β and the presence of pulmonary 
fibrosis in a chest X-ray as indicated by the presence 
or absence of lesions in post-TB patients (p < 0.05). In 
other words, the value of TGF-β was significantly 
related to the presence of fibrosis lesions. 
 
 
Discussion 
 
In this study, the majority of the subject was 
male (n = 31, 60.80%). This is in line with a study 
conducted by Adhanta SR et al., (2009), Chung et al., 
(2011) and Manji et al., (2016) which found that male 
gender is more common in TB cases [11], [12], [13]. In 
this study, the majority of participants was in the age 
group 46-60. According to the Indonesian Ministry of 
Health for the Prevention of Tuberculosis 2016, the 
most vulnerable groups of TB infections were young 
and productive age group [14]. On the other hand, 
based on 2013 Foundational Health Research in 
Indonesia, the age group > 45 years old has a higher 
prevalence among other groups [15]. 
This study found that 42 subjects (82.4%) had 
fibrosis lesions on chest X-ray. The fibrosis lesions 
also presented in the chest X-Ray of patients that had 
been recovered from TB. The presence of sequelae 
lesions is varied. Menon et al., (2015) found 40.36% 
of patients had residual lesions, including: fibrosis 
(38.7%), cavity (21.4%), bronchiectasis (4.3%) and 
calcification (3%) [16]. The presence of these fibrosis 
lesions correlates with TGF-β levels. Based on the 
Independent T-Test, the p-value was 0.001. This 
result indicated that there was a significant correlation 
between TGF-β level and the presence of pulmonary 
fibrosis in chest X-ray (p < 0.05). 
TGF-β plays a role in growth regulators and 
cell differentiation. TGF-β is produced as an inactive 
form in part of a larger molecule that requires an acid 
or enzymatic process to activate. TGF-β is present in 
various tissues and interacts with specific cell 
membrane receptors [17], [18]. 
The importance of TGF-β in causing and 
maintaining fibrosis was seen in high levels of TGF-β 
in various fibrosis diseases as shown by few studies 
[19], [20]. This positive feedback process could 
explain the important role of TGF-β in promoting, 
strengthening and perpetuating fibrosis. Therefore, a 
potential therapeutic target for fibrosis might involve 
disconnecting one of the links with TGF-β induction 
found in myofibroblasts [19], [20]. 
TGF-β contributes to the differentiation of 
myofibroblasts by stimulating the expression of α-sma. 
TGF-β also activates myofibroblasts and then produce 
greater amounts of Extracellular Matrix protein, 
stimulating chemotaxis migration of fibroblasts to the 
inflammation site, and increasing myofibroblast ability 
to contract. In addition to increasing α-sma 
expression, TGF-β induces stress fibre formation and 
adhesion complex maturation. TGF-β also induces the 
biochemical release of contraction of stress fibres. In 
the other study, TGF-β also acts as the main mediator 
of EMT, providing a further source for myofibroblasts. 
This explains the TGF-β involvement in the 
pathogenesis of fibrosis found in various organs and 
tissues. TGF-β is considered a "major switch" in 
fibrotic processes, plays a role in parenchymal and 
interstitial fibrosis, as well as vascular remodelling. 
Thus the therapeutic target in diseases with 
fibrogenesis should target the TGF-β pathway. Many 
attempts have been made to block TGF-β. 
Pirfenidone, recently approved for the treatment of 
IPF, weakens the production and work of TGF-β, 
albeit with an unclear mechanism [21], [22], [23], [24]. 
In conclusion, there is a correlation between 
TGF-β level with the presence of pulmonary fibrosis in 
chest X-ray in post-pulmonary tuberculosis patients. 
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